Top Searches
Advertisement

Rub, Pop, Repeat: Why Painkillers Are India’s New Lifestyle Staple


Updated: July 19, 2025 08:38

Image Source : Emergency Dentist London
India’s pain relief industry has doubled in size over five years, now valued at Rs 15,905 crore as of May 2025. This explosive 18% CAGR outpaces the broader OTC market, which grew at 6% CAGR to Rs 80,000 crore.
 
Key Highlights
 
- Analgesics dominate with 75% market share; paracetamol leads the pack

- Rubefacients (topical creams and gels) like Omnigel are gaining traction

- Over 2,700 brands now compete, up from 1,552 in 2020

- Popular drugs include Dolo, Zerodol SP, Ultracet, Calpol, Saridon, and Ibugesic Plus
 
Drivers of Growth

- Urban lifestyle shifts: gym injuries, chronic stress, and sedentary habits

- Post-Covid awareness: consumers now prioritize immediate pain relief

- Ease of access: prescription drugs increasingly available OTC

- Rising self-medication despite medical warnings
 
Emerging Concerns

- Experts warn of kidney damage and other risks from prolonged use

- Self-medication trend extends to derma products, now a Rs 14,854 crore market

- Gen Z is driving demand for skin creams and anti-inflammatory solutions
 
Industry Voices

- Cipla Health’s MD cites demand for fast, convenient formats

- Bayer’s South Asia head notes changing attitudes toward pain and productivity

- Physicians link rising demand to obesity, anxiety, and lack of sleep
 
Outlook
Pain relief is no longer just a symptom fix—it’s a lifestyle staple. But as convenience rises, so does the need for caution.
 
Source: The Economic Times, PharmaTrac, ET Pharma

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement